Dopamine and dopamine-related ligands can bind not only to dopamine receptors

J Myslivecek - Life, 2022 - mdpi.com
The dopaminergic system is one of the most important neurotransmitter systems in the
central nervous system (CNS). It acts mainly by activation of the D1-like receptor family at the …

Recent advances towards the discovery of dopamine receptor ligands

A Zhang, Y Kan, F Li - Expert Opinion On Therapeutic Patents, 2006 - Taylor & Francis
Dopamine is a key regulator in the CNS, contributing importantly to functions of arousal and
attention, initiation of movement, perception, motivation and emotion. Its imbalance has …

Current drug treatments targeting dopamine D3 receptor

GM Leggio, C Bucolo, CBM Platania… - Pharmacology & …, 2016 - Elsevier
Dopamine receptors (DR) have been extensively studied, but only in recent years they
became object of investigation to elucidate the specific role of different subtypes (D1R, D2R …

Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds

AE Moritz, RB Free, DR Sibley - Cellular signalling, 2018 - Elsevier
Compounds that target D2-like dopamine receptors (DRs) are currently used as therapeutics
for several neuropsychiatric disorders including schizophrenia (antagonists) and …

Targeting the receptor-based interactome of the dopamine D1 receptor: looking for heteromer-selective drugs

V Casadó-Anguera, A Cortés, V Casado… - Expert opinion on drug …, 2019 - Taylor & Francis
Introduction: G protein-coupled receptors (GPCRs) are a superfamily of membrane proteins
highly expressed in the brain that are involved in almost all functions of the CNS. During the …

Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases

S Maramai, S Gemma, S Brogi, G Campiani… - Frontiers in …, 2016 - frontiersin.org
D3 receptors represent a major focus of current drug design and development of
therapeutics for dopamine-related pathological states. Their close homology with the D2 …

Dopamine receptor subtype-selective drugs: D2-like receptors

O Prante, M Dörfler, P Gmeiner - The dopamine receptors, 2010 - Springer
Drugs that are known to activate or block dopamine receptors are widely used for the
treatment of a number of severe diseases. In most cases, dopaminergic drugs preferentially …

Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders

A Zhang, JL Neumeyer, RJ Baldessarini - Chemical reviews, 2007 - ACS Publications
Dopamine (DA) is a critical neurotransmitter in the mammalian central nervous system
(CNS). The cerebral dopaminergic system is implicated in the pathophysiology of several …

Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

JM Beaulieu, E Borrelli, A Carlsson… - IUPHAR/BPS guide to …, 2019 - journals.ed.ac.uk
Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology
Database Page 1 IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F20/2019.4 …

Dopamine D2 receptors dimers: how can we pharmacologically target them?

M Carli, S Kolachalam, S Aringhieri… - Current …, 2018 - ingentaconnect.com
Background: Dopamine D2 and D3 receptors can form homo-and heterodimers and are
important targets in Schizophrenia and Parkinson's. Recently, many efforts have been made …